Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "CDMO"

373 News Found

Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
News | November 28, 2025

Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight


Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
News | November 21, 2025

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub


Remedium Lifecare posts consolidated Q2 FY26 net profit higher at Rs. 8.62 Cr
News | November 17, 2025

Remedium Lifecare posts consolidated Q2 FY26 net profit higher at Rs. 8.62 Cr

Consolidated revenue from operations stood at Rs. 111.05 crore


Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities
News | November 13, 2025

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million


JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
News | November 12, 2025

JB Pharma Q2 PAT up 19 % at Rs. 208 Cr

Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore


Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
News | November 04, 2025

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal


India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
News | October 31, 2025

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Syngene International expands capabilities with new bioconjugation suite in Bengaluru
News | October 25, 2025

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services